Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | GLS | O94925 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | APAF1 | O14727 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4573076 | 0.85 | KDM4E (0.65) | KDM4ELMNAGLSPOLBAPAF1 | |
| SCHEMBL21093388 | 0.82 | KDM4E (0.61) | KDM4ELMNAGLSPOLBAPAF1 | |
| SCHEMBL9696618 | 0.82 | KDM4E (0.57) | KDM4ELMNAPOLBAPAF1MAPK1 | |
| SCHEMBL113242 | 0.81 | LMNA (1.00) | KDM4ELMNAGLSPOLBAPAF1 | |
| SCHEMBL8270927 | 0.81 | KDM4E (0.59) | KDM4ELMNAGLSPOLBKMT2A | |
| SCHEMBL22932731 | 0.80 | KDM4E (0.71) | KDM4ELMNAGLSPOLBAPAF1 | |
| SCHEMBL23954030 | 0.80 | KDM4E (0.54) | KDM4ELMNAPOLBAPAF1MAPK1 | |
| SCHEMBL21806760 | 0.80 | KDM4E (0.58) | KDM4ELMNAGLSPOLBKMT2A | |
| SCHEMBL17489160 | 0.80 | GLS (0.75) | KDM4ELMNAGLSPOLBAPAF1 | |
| SCHEMBL18141977 | 0.79 | KDM4E (0.61) | KDM4ELMNAGLSPOLBAPAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11560357-B2 | Methods of producing pyrazole compounds | TORRENT PHARMACEUTICALS LIMITED (IN) | 2023-01-24 | — | — | US | disclosed |
| US-20220033358-A1 | METHODS OF PRODUCING PYRAZOLE COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2022-02-03 | — | — | US | disclosed |
| US-11155567-B2 | Sting agonist compounds and methods of use | MERSANA THERAPEUTICS, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| CN-113166069-A | Process for producing pyrazole compound | 托伦特药物有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20210032269-A1 | STING AGONIST COMPOUNDS AND METHODS OF USE | MERSANA THERAPEUTICS, INC. | 2021-02-04 | — | — | US | disclosed |
| CN-102414168-B | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD | 2014-05-21 | — | — | CN | disclosed |
| US-8563714-B2 | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-22 | — | — | US | disclosed |
| EP-2432760-B1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-10 | — | — | US | disclosed |
| CN-102414168-A | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD | 2012-04-11 | — | — | CN | disclosed |
| EP-2432760-A1 | BRIDGED SPIRO [2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010134014-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | FPR1, FPR2, FPR3 | KDM4E 4642/4885LMNA 2368/4885GLS 3998/4885 |
| US-11560357-B2 | Methods of producing pyrazole compounds | TPO, TSHR, PDXK | KDM4E 1216/4885LMNA 3404/4885GLS 1733/4885 |
| US-11155567-B2 | Sting agonist compounds and methods of use | STING1, IRF3, MAVS | KDM4E 3706/4885LMNA 2038/4885GLS 821/4885 |
| US-20210032269-A1 | STING AGONIST COMPOUNDS AND METHODS OF USE | STING1, IRF3, MAVS | KDM4E 3706/4885LMNA 2038/4885GLS 821/4885 |
| US-20220033358-A1 | METHODS OF PRODUCING PYRAZOLE COMPOUNDS | TPO, TSHR, PDXK | KDM4E 1216/4885LMNA 3404/4885GLS 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.